1. Galanos LJK, Rijken A, Elferink MAG, Kok NFM, van Erning FN, De Hingh IHJT. Influence of a nationwide colorectal cancer screening program on the incidence of synchronous colorectal peritoneal metastases. Int J Cancer. 2025 Jul 15;157(2):232-238.
2. van Maaren MC, Voorham QJM, Wijnen EM, de Munck L, Wesseling J, Visser O, Siesling S. Notification of locoregional breast cancer recurrence based on pathology reports: A nationwide validation study with the Netherlands Cancer Registry. Cancer Epidemiol. 2025 Jun;96:102780.
3. Kuijper SC, Gehrels AM, van der Geest LG, Verhoeven RHA, Koerkamp BG, Molenaar IQ, Stommel MWJ, de Meijer VE, de Vos-Geelen J, Wumkes ML, Besselink MG, Wilmink JW, van Laarhoven HWM; Dutch Pancreatic Cancer Group. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Int J Cancer. 2025 May 1;156(9):1726-1735.
4. Darai A, Koëter T, van Erning FN, van Alphen RJ, Verheul HMW, Verheij M, Zimmerman DDE, Vissers PAJ, de Wilt JHW. The role of adjuvant chemotherapy in rectal cancer: A nationwide cohort study from the Netherlands. Colorectal Dis. 2025 Mar;27(3):e70054.
5. Jutten E, van Kempen LCLT, Diercks GFH, van Leeuwen BL, Kruijff S, Wevers KP. Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma. Mol Diagn Ther. 2025 Mar;29(2):229-238.
6. Yildirim H, Richters A, Bins AD, Postema AW, Aarts MJB, van Oijen MGH, Zondervan PJ, Aben KKH. Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort. Eur Urol Open Sci. 2025 Feb 10;72:42-45.
7. van Doorn-Wink KCJ, Postmus PE, de Ruysscher D, Damhuis RAM. Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands. Radiother Oncol. 2025 Feb;203:110661.
8. van Laarhoven H, Verhoeven R, van Berge Henegouwen M, Mohammad NH, van Hillegersberg R, Slingerland M, Muijs CT, Wijnhoven B, Mostert B, Beerepoot L, Nieuwenhuijzen G, Derks S, van Rossum PSN. Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands. EClinicalMedicine. 2025 Jan 22;80:103067.
9. Westerveld ASR, Tytgat GAM, van Santen HM, van Noesel MM, Loonen J, de Vries ACH, Louwerens M, Koopman MMW, van der Heiden-van der Loo M, Janssens GO, de Krijger RR, Ronckers CM, van der Pal HJH, Kremer LCM, Teepen JC. Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study. J Clin Oncol. 2025 Jan 10;43(2):154-166.
10. Mülder DT, van de Schootbrugge-Vandermeer HJ, O'Mahony JF, Sun D, Han W, Verhoeven RHA, van Loo M, van de Veerdonk W, Spaander MCW, Lansdorp-Vogelaar I. Gastric Cancer Risk among Immigrants and Socioeconomic Groups in the Netherlands. Cancer Epidemiol Biomarkers Prev. 2025 Jan 9;34(1):85-92.